作者： 来源： 时间：2025-02-17

2025年2月12日至14日，第16届亚洲制药展览会（Asia Pharma Expo）在孟加拉达卡国际会展中心盛大举行。作为南亚地区规模最大的制药行业盛会，本届展会吸引了来自32个国家和地区的800余家企业参展，专业观众超1.4万人次。宁夏惟远（Synvent）首次亮相即成为焦点，凭借其绿色创新技术和高性价比的药用辅料解决方案，为南亚医药供应链注入新动能。

From February 12 to 14, 2025, the 16th Asia Pharma Expo was grandly held at the Dhaka International Convention Center in Bangladesh. As the largest pharmaceutical industry event in South Asia, this edition attracted over 800 exhibitors from 32 countries and regions, drawing more than 14,000 professional attendees. Making its debut at the expo, Ningxia Synvent emerged as a focal point, injecting new momentum into South Asia’s pharmaceutical supply chain with its green innovation technologies and cost-effective excipient solutions.

孟加拉凭借WTO专利豁免政策（有效期至2033年）及年均12%的行业增速，已跃升为全球仿制药生产与出口的核心枢纽。其本土药企不仅满足国内97%的药品需求，更将产品出口至127个国家。然而，当地辅料市场长期依赖进口，高端产品需从欧洲采购，成本高昂。惟远瞄准这一痛点，推出符合欧美药典标准的高纯度PVP（聚维酮）系列产品，结合较欧洲供应商低20%-30%的定价策略，为南亚药企提供兼具质量与成本优势的解决方案。

Leveraging the WTO patent exemption policy (valid until 2033) and an annual industry growth rate of 12%, Bangladesh has ascended as a global hub for generic drug production and exports. Its domestic pharmaceutical companies not only fulfill 97% of local medication demand but also export products to 127 countries. However, the local excipient market remains heavily reliant on imports, particularly high-end products sourced from Europe at premium costs. Addressing this pain point, Synvent introduced its high-purity PVP (Polyvinylpyrrolidone) series compliant with USP/EP pharmacopeia standards. With a pricing strategy 20%-30% lower than European suppliers, the company offers South Asian pharmaceutical manufacturers a balanced solution of quality and affordability.

展会期间，惟远通过创新互动策略高效链接客户资源。依托PPT动态演示、二维码数字化产品手册及虚拟工厂实景导览，直观呈现全产业链整合能力、智能化控制中心及尖端研发实力。短短三日，团队累计接待专业访客超100人次，与孟加拉头部药企及分销商达成多项样品测试协议、工厂审计预约，并收获多家企业的年度合作意向。

During the expo, Synvent efficiently connected with clients through innovative interactive strategies. Dynamic PPT presentations, QR code-enabled digital catalogs, and virtual factory tours vividly showcased its vertically integrated supply chain, intelligent control centers, and cutting-edge R&D capabilities. Over three days, the team engaged with over 100 professional visitors, securing multiple sample testing agreements, factory audit appointments with leading Bangladeshi pharmaceutical companies and distributors, and annual cooperation intentions from several partners.
惟远重点展示的绿色制造体系引发广泛关注。通过清洁生产工艺降低能耗，叠加自有300MW光伏项目大幅减少碳排放，其低碳路径与南亚市场的可持续发展目标深度契合。孟加拉医药工业协会（BAPI）代表评价称：“绿色辅料是行业升级的关键，惟远的技术实践为区域供应链转型提供了标杆。”

Synvent’s green manufacturing system garnered significant attention. By reducing energy consumption through clean production processes and slashing carbon emissions via its 300MW photovoltaic project, the company’s low-carbon approach aligns deeply with South Asia’s sustainable development goals. A representative from the Bangladesh Association of Pharmaceutical Industries (BAPI) commented: “Green excipients are pivotal for industry advancement. Synvent’s technological practices set a benchmark for regional supply chain transformation.”
惟远南亚首秀以“技术实力+灵活服务”赢得市场信任。随着孟加拉政府计划2026年下调辅料进口关税，以及印度市场逐步开放，公司“高性价比+绿色低碳”双引擎战略将进一步释放潜力。惟远将持续深化本土合作，为全球仿制药供应链的提质增效与低碳转型提供最佳解决方案。

Synvent’s South Asia Debut Earns Market Trust Through “Technical Expertise + Agile Services” .With Bangladesh’s planned reduction in excipient import tariffs by 2026 and India’s gradual market liberalization, the company’s dual-engine strategy of “cost-effectiveness + green low-carbon” is poised to unlock greater potential. Synvent will further deepen local collaborations, delivering best-in-class solutions to enhance quality, efficiency, and low-carbon transformation within the global generic drug supply chain.